Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

NEW ISSUE: AstraZeneca US$ Bnchmrk 5s/7s/10s 3-Pt; T+65A/T+75A/T+85A

IGC US Market: Deal Flow - GeneralIGC European Market: Deal Flow - General

AstraZeneca Finance LLC (AZN) exp A1/A+ (s/s) US$ benchmark SEC registered 3-part sr notes (5y FXD due 3/2/31, 7y FXD due 3/2/33 and 10y FXD due 3/2/36). MWC then 1mo par call on 5y (2/2/31), 2mos on 7y (1/2/33) and 3mos on 10y (12/2/35). BofA (B&D)/DB/HSBC/Miz joint active books. Guarantor: AstraZeneca PLC. Denoms: 2,000 x 1,000. Sales into Canada: Yes, via exemption. Listing: New York Stock Exchange. UOP: General corporate purposes, which may include the refinancing of existing indebtedness.Pricing 2/25. Settle 3/2 (T+3). IPTs: 5y T+65 area, 7y T+75 area, 10y T+85 area.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.